Mucosal vaccine composition

Patent metadata

Field	Value
Publication number	US-2016193327-A1
Application number	US-201414917084-A
Country	US
Kind code	A1
Filing date	Oct 2, 2014
Priority date	Oct 3, 2013
Publication date	Jul 7, 2016
Grant date	—

Abstract

The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

First claim

1 . A mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the mucosal vaccine composition comprising:
at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

2 . The mucosal vaccine composition according to claim 1 , being a liquid preparation, a nebular, a semisolid preparation, or a solid preparation,
wherein said semi-solid preparation and said solid preparation dissolve by a body fluid and/or body temperature.

3 . The mucosal vaccine composition according to claim 2 , being a solid preparation that dissolves by a body fluid and/or body temperature.

4 . The mucosal vaccine composition according to claim 1 , to be used for inducing humoral immunity.

5 . The mucosal vaccine composition according to claim 1 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

6 . The mucosal vaccine composition according to claim 2 , to be used for inducing humoral immunity.

7 . The mucosal vaccine composition according to claim 3 , to be used for inducing humoral immunity.

8 . The mucosal vaccine composition according to claim 2 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

9 . The mucosal vaccine composition according to claim 3 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

10 . The mucosal vaccine composition according to claim 4 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

11 . The mucosal vaccine composition according to claim 6 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

12 . The mucosal vaccine composition according to claim 7 , wherein the antigen is an antigen derived from an infectious disease or a cancer antigen.

Assignees

• Nitto Denko Corp

Inventors

• Fukasaka Masahiro
• Hori Mitsuhiko
• Okubo Katsuyuki
• Asari Daisuke
• Okazaki Arimichi
• KIYOTOH Eiji
• Matsushita Kyohei

Classifications

• C12N2730/10134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/32634

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18434

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/20

  Rubella virus · CPC title

• A61K39/12

  Viral antigens · CPC title